Abstract
Acute coronary syndrome (ACS) remains the leading cause of death in the industrialised world and is ever increasing in developing populations. This study assesses the safety and effectiveness of atorvastatin 40 mg in meeting new targets for lipids in patients presenting to the coronary care unit with ACS. A group of 79 consecutive patients admitted with ACS were initiated on or changed to atorvastatin 40 mg during admission. The reduction in total cholesteron (TC), low density lipoprotein-cholesterol (LDL-C) and incidence of any adverse effects were assessed at one week, one month and three months after hospitalisation. At baseline only 13% and 23% of patients had their TC and LDL-C respectively within Joint British Societies 2 (JBS2) national institute for Health and Clinical Excellence (NICE) targets for patients with cardiovascular disease. After 1 month of atorvastatin therapy these values had increased to 77% and 70% respectively with an absolute reduction in TC and LDL-C of 30%. At baseline 47% and 50% of patients had TC and LDL-C within National Service framework (NSF) targets at baseline, however, 1 week after atorvastatin therapy the proportion of patients achieving NSF targets increased to 88% and 84% for TC and LDL-C respectively. These data suggest that early and intensive reduction of lipids with atorvastatin 40 mg for ACS patients in hospital is a safe and effective strategy to meet recommended targets for lipids. Br J Diabetes Vasc Dis 2008; 8: 286—290
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: The British Journal of Diabetes & Vascular Disease
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.